MCL1 and neoplasm: Breast cancer stem cells are known to be responsible for recurrence and resistance to therapy; therefore, the requirement for MCL-1 in breast cancer stem cell activity, the regression of established tumours upon loss of MCL-1 and the association between high MCL1 and stemness markers across a range of breast cancer patients indicate that targeting MCL-1 could be harnessed to improve breast cancer outcome.